MedTrace Logo

Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

NCT00395434 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-10-31

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced solid tumors. The maximum tolerated dose will be defined if it is at one of the three dose levels under study.

Conditions

Interventions

DRUG

Combretastatin A4 Phosphate (CA4P)

DRUG

Bevacizumab (Avastin)

Sponsors & Collaborators

  • Mateon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Paul Nathan, MD · Mount Vernon Hospital

  • Hillori Connors, MS · Mateon Therapeutics

  • Peter Harris, MD · Mateon Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395434 on ClinicalTrials.gov